Vector Science and Therapeutics (TSXV:PAIN) ROCE %: -53.89% (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:PAIN Vector Science and Therapeutics Corp TSXV:PAIN
14 GF Score
Price C$1.55
View Full Analysis

What is Vector Science and Therapeutics ROCE %?

Vector Science and Therapeutics TSXV:PAIN -4.32% 14 ROCE % is -53.89% as of Feb. 2026. GuruFocus rates TSXV:PAIN with a GF Score™ of 14/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vector Science and Therapeutics's annualized ROCE % for the quarter that ended in Feb. 2026 was -53.89%.

Vector Science and Therapeutics  (TSXV:PAIN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vector Science and Therapeutics ROCE % Related Terms

Vector Science and Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Vector Science and Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vector Science and Therapeutics ROCE % Chart

Vector Science and Therapeutics Annual Data
Trend Aug24 Aug25
ROCE %
0.00 -59.86

Vector Science and Therapeutics Quarterly Data
Aug24 Nov24 Aug25 Nov25 Feb26
ROCE % 0.00 0.00 0.00 -164.17 -53.89
TSXV:PAIN
14GF Score
Vector Science and Therapeutics Corp TSXV:PAIN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vector Science and Therapeutics ROCE % Calculation

Vector Science and Therapeutics's annualized ROCE % for the fiscal year that ended in Aug. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=-1.137/( ( (0.001 - 0) + (4.146 - 0.348) )/ 2 )
=-1.137/( (0.001+3.798)/ 2 )
=-1.137/1.8995
=-59.86 %

Vector Science and Therapeutics's ROCE % of for the quarter that ended in Feb. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Feb. 2026 )  (Q: Nov. 2025 )(Q: Feb. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Feb. 2026 )  (Q: Nov. 2025 )(Q: Feb. 2026 )
=-1.316/( ( (3.137 - 0.415) + (2.263 - 0.101) )/ 2 )
=-1.316/( ( 2.722 + 2.162 )/ 2 )
=-1.316/2.442
=-53.89 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -53.89% mean?
Vector Science and Therapeutics (TSXV:PAIN) has a ROCE % of -53.89% as of Feb. 2026.
Is Vector Science and Therapeutics' ROCE % too high?
Vector Science and Therapeutics' current ROCE % is -53.89%. Overall, Vector Science and Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Vector Science and Therapeutics' ROCE % compare to ABT and SYK?
Vector Science and Therapeutics' ROCE % of -53.89% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.22, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vector Science and Therapeutics's current ROCE % is -53.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vector Science and Therapeutics stock overvalued right now?
Vector Science and Therapeutics (TSXV:PAIN) has a current ROCE % of -53.89%. The current ROCE % is -53.89%. Vector Science and Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vector Science and Therapeutics (TSXV:PAIN), the current ROCE % is -53.89% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vector Science and Therapeutics Business Description

Vector Science and Therapeutics Corp develops novel biomechanical devices and active transdermal drug and peptide delivery platforms to equip clinicians with non-systemic, localized interventions targeting a broad cross-section of diseases and conditions where systemic delivery of interventions compromises the therapeutic effect or introduces unacceptable harm.
14GF Score

Get the complete analysis for TSXV:PAIN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$1.55
Price